Tabriziani Hossein, Baron Pedro, Abudayyeh Islam, Lipkowitz Michael
Transplant Nephrology Attending, Balboa Institute of Transplant (BIT), Balboa Nephrology Medical Group (BNMG), San Diego, CA, USA.
Surgical Director of Pancreas Transplant, Transplant Institute, Loma Linda University, Loma Linda, CA, USA.
Clin Kidney J. 2019 Apr 25;12(4):576-585. doi: 10.1093/ckj/sfz039. eCollection 2019 Aug.
Cardiovascular disease is a leading cause of morbidity and mortality and is becoming more prevalent as the population ages and risk factors increase. This is most apparent in the end-stage renal disease (ESRD) patient population. In part, this is due to cofactors such as diabetes and hypertension commonly predisposing to progressive renal disease, as well as being a direct consequence of having renal failure. Of all major organ failures, kidney failure is the most likely to be managed chronically using renal replacement therapy and, ultimately, transplant. However, lack of transplant organs and a large renal failure cohort means waiting lists are often quite long and may extend to 5-10 years. Due to the cardiac risk factors inherent in patients awaiting transplant, many succumb to cardiac issues while waiting and present an increased per-procedural cardiac risk that extends into the post-transplant period. We aim to review the epidemiology of coronary artery disease in this population and the etiology as it relates to ESRD and its associated co-factors. We also will review the current approaches, recommendations and evidence for management of these patients as it relates to transplant waiting lists before and after the surgery. Recommendations on how to best manage patients in this cohort revolve around the available evidence and are best customized to the institution and the structure of the program. It is not clear whether the revascularization of patients without symptoms and with a good functional status yields any improvement in outcomes. Therefore, each individual case should be considered based on the risk factors, symptoms and functional status, and approached as part of a multi-disciplinary assessment program.
心血管疾病是发病和死亡的主要原因,并且随着人口老龄化和风险因素的增加而变得更加普遍。这在终末期肾病(ESRD)患者群体中最为明显。部分原因是糖尿病和高血压等辅助因素通常易导致进行性肾病,同时也是肾衰竭的直接后果。在所有主要器官衰竭中,肾衰竭最有可能通过肾脏替代疗法进行长期管理,并最终进行移植。然而,缺乏移植器官以及大量肾衰竭患者意味着等待名单往往很长,可能会延长至5至10年。由于等待移植患者存在固有的心脏危险因素,许多人在等待期间死于心脏问题,并且在围手术期呈现出增加的心脏风险,这种风险会延续到移植后时期。我们旨在回顾该人群中冠状动脉疾病的流行病学及其与ESRD及其相关辅助因素相关的病因。我们还将回顾与手术前后移植等待名单相关的这些患者管理的当前方法、建议和证据。关于如何最佳管理该队列患者的建议围绕现有证据展开,并且最好根据机构和项目结构进行定制。对于无症状且功能状态良好的患者进行血运重建是否能改善结局尚不清楚。因此,应根据危险因素、症状和功能状态对每个病例进行评估,并作为多学科评估项目的一部分来处理。